Valeant Pharmaceuticals International
Allergan sets up meeting to seek shareholder OK of Actavis acquisition

Allergan Inc., the Irvine company that makes Botox, scheduled a March 10 special meeting to seek shareholder approval of its acquisition by Irish firm Actavis. Actavis agreed in November to pay about $66 billion in cash and stock to acquire Allergan, which had spent several months battling a hostile takeover attempt by Canadian company Valeant Pharmaceuticals International Inc. The deal needs the approval of shareholders of both companies. Actavis has also scheduled a March 10 meeting to seek shareholder approval of the acquisition. Actavis and Allergan expect to begin mailing a joint proxy statement — disclosing details of the sale — to their respective shareholders...